MicroRNA Assay for High-Risk IPMN Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to accurately differentiate between high-risk and low-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas, which are precursors to pancreatic cancer, leading to challenges in management and potential missed opportunities for early detection and treatment.
Innovation Solution
Identification of differentially expressed microRNAs (miRNAs) in samples, such as blood or pancreatic cyst fluid, to serve as biomarkers for distinguishing high-risk IPMNs requiring resection from low-risk IPMNs that can be monitored, using microarrays and assays to detect miRNA expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to manage IPMNs, then clinical guidelines can be followed, but accurate differentiation between high-risk and low-risk IPMNs cannot be achieved
Solution Approach 1:
The patent introduces microRNA expression profiles as an intermediary biomarker system that mediates between the structural imaging findings and clinical management decisions. By measuring miRNA expression levels in pancreatic cyst fluid, the system provides an objective molecular basis for risk stratification that improves both measurement precision and management reliability.
Solution Approach 2:
The patent shifts the diagnostic parameter from morphological imaging characteristics to molecular expression profiles. By quantifying miRNA expression levels and using these quantitative parameters to define risk categories, the system achieves more precise risk differentiation while maintaining reliability in clinical management decisions.
2Measurement precision
If invasive diagnostic procedures are performed to detect pancreatic cancer, then early detection is achieved, but patient morbidity and procedural complexity increase
Solution Approach 1:
The patent uses pancreatic cyst fluid as an intermediary sampling medium that non-invasively captures molecular information from the pancreatic lesion. By analyzing miRNA expression in this readily obtainable fluid sample, the system achieves early detection accuracy without requiring complex invasive procedures or tissue biopsies.
Solution Approach 2:
The patent replaces mechanical tissue biopsy procedures with a molecular analysis approach. Instead of physically removing tissue for examination, the system uses molecular markers (miRNAs) in cyst fluid to detect cancer risk, substituting a less invasive molecular detection mechanism for complex mechanical procedures.
3Measurement precision
If multiple diagnostic tests are performed to assess IPMN risk, then diagnostic accuracy improves, but test complexity and time required increase
Solution Approach 1:
The patent develops a universal miRNA expression profiling approach that simultaneously performs multiple diagnostic functions: risk stratification, progression prediction, and treatment guidance. By using a single molecular assay platform to address multiple diagnostic needs, the system improves accuracy without proportionally increasing time or complexity.
Solution Approach 2:
The patent segments the diagnostic process into distinct risk categories (low-risk, intermediate-risk, high-risk) based on miRNA expression thresholds. This segmentation allows for streamlined diagnostic algorithms where patients can be rapidly classified into appropriate management categories, reducing overall testing time while maintaining high diagnostic accuracy.
Data Source
AI summary
The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.